- Home
- TLSA vs ELTX Comparison
TLSA vs ELTX Comparison
Compare TLSA & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- ELTX
- Stock Information
- Founded
- TLSA 2013
- ELTX 2011
- Country
- TLSA United Kingdom
- ELTX United States
- Employees
- TLSA N/A
- ELTX N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- ELTX Health Care
- Exchange
- TLSA Nasdaq
- ELTX Nasdaq
- Market Cap
- TLSA 240.0M
- ELTX 158.5M
- IPO Year
- TLSA 2000
- ELTX N/A
- Fundamental
- Price
- TLSA $1.89
- ELTX $10.16
- Analyst Decision
- TLSA
- ELTX Strong Buy
- Analyst Count
- TLSA 0
- ELTX 2
- Target Price
- TLSA N/A
- ELTX $11.00
- AVG Volume (30 Days)
- TLSA 342.2K
- ELTX 89.8K
- Earning Date
- TLSA 05-06-2025
- ELTX 11-12-2025
- Dividend Yield
- TLSA N/A
- ELTX N/A
- EPS Growth
- TLSA N/A
- ELTX N/A
- EPS
- TLSA N/A
- ELTX N/A
- Revenue
- TLSA N/A
- ELTX N/A
- Revenue This Year
- TLSA N/A
- ELTX N/A
- Revenue Next Year
- TLSA N/A
- ELTX N/A
- P/E Ratio
- TLSA N/A
- ELTX N/A
- Revenue Growth
- TLSA N/A
- ELTX N/A
- 52 Week Low
- TLSA $0.63
- ELTX $4.05
- 52 Week High
- TLSA $2.60
- ELTX $12.62
- Technical
- Relative Strength Index (RSI)
- TLSA 44.11
- ELTX 45.61
- Support Level
- TLSA $1.81
- ELTX $9.50
- Resistance Level
- TLSA $2.10
- ELTX $10.14
- Average True Range (ATR)
- TLSA 0.16
- ELTX 0.48
- MACD
- TLSA -0.03
- ELTX -0.04
- Stochastic Oscillator
- TLSA 14.29
- ELTX 39.96
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.